S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

Sathe, KinnariMaetzler, WalterLang, JohannesMounsey, Ross BrianFleckenstein, CorinnaMartin, Heather LouiseSchulte, ClaudiaMustafa, SarahSynofzik, MatthisVukovic, ZvonimirItohara, ShigeyoshiBerg, DanielaTeismann, Peter2013-04-042013-04-042012-11Sathe, K, Maetzler, W, Lang, J, Mounsey, R B, Fleckenstein, C, Martin, H L, Schulte, C, Mustafa, S, Synofzik, M, Vukovic, Z, Itohara, S, Berg, D & Teismann, P 2012, 'S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway', Brain, vol. 135, no. 11, pp. 3336-3347. https://doi.org/10.1093/brain/aws2500006-8950http://hdl.handle.net/2164/2763121278729engcalcium-binding proteinMPTPParkinson's diseaseS100BR MedicineRS100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayJournal article10.1093/brain/aws25013511